BioTime Licenses Matrix for Eye Drug Delivery and Echo Therapeutics Expands License Agreement to Deliver Anesthetic
Recently, I pointed out that BioTime Inc. (AMEX: BTX) has significant short-term opportunities for licensing the company's HyStem hydrogel. Today, BioTime announced the first such deal. Jade Therapeutics LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform, has signed an exclusive sublicense agreement and a supply agreement with BioTime.
BioTime “will provide Jade with clinical-grade HyStem hydrogels and certain patented technology for use by Jade Therapeutics in the development of new pharmaceutical products for ophthalmologic use. Jade plans to utilize the hydrogels to facilitate time-release topical delivery of recombinant human growth hormone to help heal lesions on the ocular surface.”
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.